Designed for modern high-stress lifestyles and diverse dietary habits, including frequent seafood consumption and social dining occasions, Red Crystallization Strategy is formulated as a daily nutritional supplement. Developed based on the concept of “scientific balance with gentle daily support,” the formula is specially designed for the needs of Asian consumers. Through a well-balanced nutritional formula and consistent daily supplementation, it helps regulate physiological functions and maintain overall wellness and lifestyle balance.

The premium formula features “2 patented technologies, ingredients sourced from 6 countries, and 9 essential nutrients.” It incorporates the Japanese patented IMIDAZOLE PEPTIDE Metabolism Formula, combined with US-patented grape seed extract, bilberry extract, and green tea extract. The product is further enriched with Vitamins C, E, B1, B6, and niacinamide sourced from internationally recognized ingredient suppliers to support daily health maintenance.

This product received the 2021 Bronze Quality Award from Monde Selection and is recommended by physicians, nutritionists, and more than 100 pharmacists across Taiwan. From raw material selection and formula development to manufacturing and final product inspection, strict quality control standards are implemented throughout every stage of production. The product is manufactured in GMP, HACCP, and ISO 22000 certified facilities to ensure consistent and reliable product quality.

• The manufacturing facility of this product, PRINCE PHARMACEUTICAL CO., LTD.－Xinpu Factory, maintains a comprehensive quality management system and holds international recognized food safety and manufacturing certifications, including:

• ISO 22000

• HACCP

• GMP

• Additionally, this product received the 2021 Bronze Quality Award from Monde Selection.

Microcrystalline Cellulose

Japanese Patented Imidazole Peptide Metabolism (Tapioca Starch, Bonito and Tuna Extract)

US Patented Grape Seed Extract

Green Tea Extract (Contains EGCG)

Vitamin C 97%

Polyvinylpyrrolidone

Hydroxypropyl Methylcellulose

Niacinamide

Silicon Dioxide

Vitamin E 50%

Bilberry Extract

Magnesium Stearate

Titanium Dioxide

Polyethylene Glycol 99.99% Compound Food Additive

Pyridoxine Hydrochloride (Vitamin B6)

Thiamine Hydrochloride (Vitamin B1)

Japanese Patented Imidazole Peptide Metabolism (Tapioca Starch, Bonito and Tuna Extract) / Accounts for 29.2% of the total main ingredients per tablet.

PRINCE PHARMACEUTICAL CO., LTD－Xinpu Factory

• Quality control measures are implemented throughout every stage of production, including raw material intake, manufacturing, packaging, and final product release, in accordance with the company’s internal quality management standards to ensure product consistency and stability.

• Raw Material Inspection: All raw materials are inspected batch by batch, including verification of batch numbers, labeling, COA documentation, and required sampling inspections.

• Packaging Material Inspection: Packaging materials are inspected batch by batch to verify labeling, specifications, appearance, material quality, and printing accuracy.

• In-Process Quality Control: Semi-finished products undergo batch sampling inspections during production, with monitoring conducted in accordance with internal process control standards.

• Production Line Inspection: Routine inspections are carried out throughout the manufacturing process to monitor environmental conditions, product appearance, and weight control.

• Metal Detection: Metal detection procedures are implemented for capsule and tablet products as a Critical Control Point (CCP) to reduce physical contamination risks.

• Packaging Line First-Article Inspection: Production begins only after confirming printing accuracy, packaging integrity, and product content correctness.

• Final Product Release Inspection: Finished products undergo final inspection in accordance with internal quality standards before warehouse release and shipment.

• Quality Record Management: Inspection records and batch production data are maintained under the internal quality management system to support product traceability and quality control.

The product undergoes regular safety testing conducted by an independent third-party testing institution. The testing items include:

Heavy Metals: Calculated as Lead (Pb) and Arsenic (As)

Microbiology: Staphylococcus aureus, Salmonella spp., and Listeria monocytogenes

Adulterated Western Medicines: Qualitative analysis of 365 common western medicine ingredients

Preservatives: Acidic preservatives

Pesticides: A total of 410 pesticide residues tested

Plasticizers: Phthalates

To ensure consistent product quality and minimize production risks, risk control measures are implemented throughout raw material intake, manufacturing, final product inspection, and post-market management in accordance with the company’s internal quality management system.

1. Preventive Quality Inspection Program: Routine inspections are conducted throughout the production process to identify and reduce potential manufacturing risks.

2. Critical Control Point (CCP) Management: Metal detection procedures are implemented for capsule and tablet products to reduce physical contamination risks.

3. Post-Market Complaint & Recall Management: The company maintains product complaint handling and recall procedures to document, investigate, and evaluate customer complaints. Corrective actions or product recalls may be initiated when necessary.

Step 1. Complaint Intake & Case Registration

Step 2. Initial Assessment & Product Verification

Step 3. Issue Reporting

Step 4. Cross-Functional Risk Assessment

Step 5. Corrective Action & Resolution Plan

Step 6. Follow-up Review & Case Closure

4. Quality Assurance & Crisis Management Mechanism: For major quality issues or product safety incidents, relevant departments jointly conduct risk assessments and implement necessary corrective actions to minimize impact and prevent recurrence.

Taiwan (Invention No. I280136): Uric acid-lowering composition containing a dipeptide of histidine and alanine.

Japan (JP2010235503A): Uric acid-lowering composition containing a dipeptide of histidine and alanine.

Japan (JP2008127355A): Composition for alleviating alcohol intoxication and foods or beverages containing the same.

USA (US 7,498,301 B2): Uric acid-lowering composition containing a dipeptide of histidine and alanine, and method for lowering uric acid using said dipeptide.